Cargando…

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma

Invasive mucinous lung adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma with no effective treatment option in advanced disease. KRAS mutations occur in 28–87% of the cases. NRG1 fusions were recently discovered in KRAS‐negative IMA cases and otherwise negative for known driver oncogenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Duruisseaux, Michaël, McLeer‐Florin, Anne, Antoine, Martine, Alavizadeh, Sanaz, Poulot, Virginie, Lacave, Roger, Rabbe, Nathalie, Cadranel, Jacques, Wislez, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224837/
https://www.ncbi.nlm.nih.gov/pubmed/27770508
http://dx.doi.org/10.1002/cam4.838
_version_ 1782493428690452480
author Duruisseaux, Michaël
McLeer‐Florin, Anne
Antoine, Martine
Alavizadeh, Sanaz
Poulot, Virginie
Lacave, Roger
Rabbe, Nathalie
Cadranel, Jacques
Wislez, Marie
author_facet Duruisseaux, Michaël
McLeer‐Florin, Anne
Antoine, Martine
Alavizadeh, Sanaz
Poulot, Virginie
Lacave, Roger
Rabbe, Nathalie
Cadranel, Jacques
Wislez, Marie
author_sort Duruisseaux, Michaël
collection PubMed
description Invasive mucinous lung adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma with no effective treatment option in advanced disease. KRAS mutations occur in 28–87% of the cases. NRG1 fusions were recently discovered in KRAS‐negative IMA cases and otherwise negative for known driver oncogenes and could represent an attractive therapeutic target. Published data suggest that NRG1 fusions occur essentially in nonsmoking Asian women. From an IMA cohort of 25 French patients of known ethnicity, driver oncogenes EGFR, KRAS, BRAF, ERBB2 mutations, and ALK and ROS1 rearrangements presence were analyzed. In the IMA samples remaining negative for these driver oncogenes, an NRG1 rearrangement detection was performed by FISH. A driver oncogene was identified in 14/25 IMA, namely 12 KRAS mutations (48%), one ROS1 rearrangement (4%), and one ALK rearrangement (4%). The detection of NRG1 rearrangement by FISH was conducted in the 11 pan‐negative IMA. One sample was NRG1 FISH‐positive and 100% of the tumor nuclei analyzed were positive. This NRG1‐positive patient was a 61‐year‐old nonsmoking woman of Vietnamese ethnicity and was the sole patient of Asian ethnicity of the cohort. She died 6 months after the diagnosis with a pulmonary multifocal disease. NRG1 FISH detection should be considered in patients with IMA pan‐negative for known driver oncogenes. These results might suggest that NRG1 fusion is more frequent in IMA from Asian patient. Larger studies are needed.
format Online
Article
Text
id pubmed-5224837
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52248372017-01-17 NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma Duruisseaux, Michaël McLeer‐Florin, Anne Antoine, Martine Alavizadeh, Sanaz Poulot, Virginie Lacave, Roger Rabbe, Nathalie Cadranel, Jacques Wislez, Marie Cancer Med Cancer Biology Invasive mucinous lung adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma with no effective treatment option in advanced disease. KRAS mutations occur in 28–87% of the cases. NRG1 fusions were recently discovered in KRAS‐negative IMA cases and otherwise negative for known driver oncogenes and could represent an attractive therapeutic target. Published data suggest that NRG1 fusions occur essentially in nonsmoking Asian women. From an IMA cohort of 25 French patients of known ethnicity, driver oncogenes EGFR, KRAS, BRAF, ERBB2 mutations, and ALK and ROS1 rearrangements presence were analyzed. In the IMA samples remaining negative for these driver oncogenes, an NRG1 rearrangement detection was performed by FISH. A driver oncogene was identified in 14/25 IMA, namely 12 KRAS mutations (48%), one ROS1 rearrangement (4%), and one ALK rearrangement (4%). The detection of NRG1 rearrangement by FISH was conducted in the 11 pan‐negative IMA. One sample was NRG1 FISH‐positive and 100% of the tumor nuclei analyzed were positive. This NRG1‐positive patient was a 61‐year‐old nonsmoking woman of Vietnamese ethnicity and was the sole patient of Asian ethnicity of the cohort. She died 6 months after the diagnosis with a pulmonary multifocal disease. NRG1 FISH detection should be considered in patients with IMA pan‐negative for known driver oncogenes. These results might suggest that NRG1 fusion is more frequent in IMA from Asian patient. Larger studies are needed. John Wiley and Sons Inc. 2016-10-21 /pmc/articles/PMC5224837/ /pubmed/27770508 http://dx.doi.org/10.1002/cam4.838 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Duruisseaux, Michaël
McLeer‐Florin, Anne
Antoine, Martine
Alavizadeh, Sanaz
Poulot, Virginie
Lacave, Roger
Rabbe, Nathalie
Cadranel, Jacques
Wislez, Marie
NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title_full NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title_fullStr NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title_full_unstemmed NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title_short NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
title_sort nrg1 fusion in a french cohort of invasive mucinous lung adenocarcinoma
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224837/
https://www.ncbi.nlm.nih.gov/pubmed/27770508
http://dx.doi.org/10.1002/cam4.838
work_keys_str_mv AT duruisseauxmichael nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT mcleerflorinanne nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT antoinemartine nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT alavizadehsanaz nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT poulotvirginie nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT lacaveroger nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT rabbenathalie nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT cadraneljacques nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma
AT wislezmarie nrg1fusioninafrenchcohortofinvasivemucinouslungadenocarcinoma